期刊
JOURNAL OF CYSTIC FIBROSIS
卷 8, 期 5, 页码 295-315出版社
ELSEVIER
DOI: 10.1016/j.jcf.2009.04.005
关键词
Cystic fibrosis; Inhaled medication; Inhalation devices
In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the Current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations Of Solutions. Additionally, we review the current knowledge oil devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction. (C) 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据